Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

UPDATE 1-UK doctors to trial ibuprofen in COVID-19 patients with breathing difficulties

Wed, 03rd Jun 2020 16:37

(Adds interview with researcher)

LONDON, June 3 (Reuters) - British doctors are trialling a
formulation of anti-inflammatory ibuprofen to see if it reduces
respiratory failure in patients with severe symptoms of
COVID-19.

The trial involves a particular formulation of ibuprofen,
which researchers said had been shown to be more effective than
standard ibuprofen for treating severe acute respiratory
distress syndrome (ARDS), a complication of COVID-19.

The formulation is already licensed for use in Britain for
other conditions.

"If successful, the global public health value of this trial
result would be immense given the low cost and availability of
this medicine," said Matthew Hotopf, director of NIHR Maudsley
Biomedical Research Centre.

The trial, known as "LIBERATE", will be a randomised study,
with recruitment of up to 230 patients expected over the coming
months.

It is being run by Guy's & St Thomas' NHS Foundation Trust
in London, King's College London (KCL) and pharmaceutical
organisation the SEEK Group.

In March, France's health minister said people should not
use anti-inflammatory drugs such as ibuprofen if they have
symptoms of COVID-19, the disease caused by the new coronavirus.

However, U.S., British and European Union drug regulators as
well as Reckitt Benckiser, which makes Nurofen, have all
said there is no evidence that ibuprofen makes COVID-19 worse.

Mitul Mehta, director of KCL's Centre for Innovative
Therapeutics, said that possible well-known gastric side effects
from ibuprofen meant that paracetamol was better to relieve
COVID-19 symptoms in its early stages.

But he added there was no evidence to back up the French
claims that ibuprofen worsens COVID-19 symptoms, saying the
formulation being used in the trial should lessen the possible
side effects.

"There's no way these early reports would've been talking
about this different formulation," Mehta told Reuters.

"The trial is the right forum in which to test the side
effects and to test the efficacy."

(Reporting by Alistair Smout; editing by Emelia
Sithole-Matarise and Ed Osmond)

Related Shares

More News
28 Apr 2021 07:55

LONDON MARKET PRE-OPEN: Covid costs hit Sainsbury; Lloyds profit jumps

LONDON MARKET PRE-OPEN: Covid costs hit Sainsbury; Lloyds profit jumps

21 Apr 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

31 Mar 2021 13:50

Reckitt Benckiser rebrands in effort to become "more memorable"

Reckitt Benckiser rebrands in effort to become "more memorable"

30 Mar 2021 09:37

BROKER RATINGS: BAE Systems, Entain and Ryanair get upgrades

BROKER RATINGS: BAE Systems, Entain and Ryanair get upgrades

26 Mar 2021 13:40

Friday broker round-up

(Sharecast News) - Ocado Group: Berenberg downgrades to hold with a target price of 2,390p.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.